REDWOOD CITY, Calif.,
May 4, 2016 /PRNewswire/ -- AcelRx
Pharmaceuticals, Inc. (Nasdaq: ACRX), a specialty pharmaceutical
company focused on the development and commercialization of
innovative therapies for the treatment of acute pain, today
announced that Senior Management will be presenting at BioEquity
Europe Conference 2016 and Bank of America Merrill Lynch 2016
Health Care Conference.
BioEquity Europe Conference 2016
Date: Wednesday, May 11
Location: Scandic Hotel, Copenhagen
Presentation Time: 11am CET
Bank of America Merrill Lynch 2016 Health Care
Conference
Date: Thursday, May
12
Location: Encore at Wynn Las Vegas
Presentation Time: 10:40 am PT,
1:40pm ET
The Bank of America presentation will be webcast live and can be
accessed through the Investors page at www.acelrx.com. For
those not available to listen to the live broadcast, a replay will
be archived for 90 days and available through the Investors page on
www.acelrx.com.
About AcelRx Pharmaceuticals, Inc.
AcelRx Pharmaceuticals, Inc. is a specialty pharmaceutical
company focused on the development and commercialization of
innovative therapies for the treatment of acute pain. The Company's
late-stage pipeline includes ARX-04 (sufentanil sublingual tablet,
30 mcg) designed for the treatment of moderate-to-severe acute pain
in a medically supervised setting; and Zalviso™ (sufentanil
sublingual tablet system) designed for the management of
moderate-to-severe acute pain in adult patients in the hospital
setting.
ARX-04 delivers 30 mcg sufentanil, a high therapeutic index
opioid, sublingually through a disposable, pre-filled, single-dose
applicator. AcelRx has reported positive results from the pivotal
Phase 3 SAP301 ambulatory surgery study, and has advanced ARX-04
into studies in emergency room patients (SAP302) and post-operative
patients 40 years and older (SAP303). Zalviso delivers 15 mcg
sufentanil sublingually through a non-invasive delivery route via a
pre-programmed, patient-controlled analgesia device. In response to
the New Drug Application (NDA) AcelRx submitted to the U.S. Food
and Drug Administration (FDA) seeking approval for Zalviso, AcelRx
received a Complete Response Letter (CRL) on July 25, 2014. The FDA has requested an
additional clinical study (IAP312), which AcelRx is planning to
initiate once production and testing of the supplies are complete,
and clinical sites are ready, in order to support its NDA
resubmission.
For additional information about AcelRx's clinical programs,
please visit www.acelrx.com.
Forward Looking Statements
This press release
contains forward-looking statements, including, but not limited to,
statements related to the process and timing of anticipated future
development of AcelRx's product candidates, ARX-04 (sufentanil
sublingual tablet, 30 mcg) and Zalviso™ (sufentanil sublingual
tablet system), including the planned initiation of the IAP312
clinical trial for Zalviso; anticipated resubmission of the Zalviso
NDA to the U.S. Food and Drug Administration, or FDA; and the
therapeutic and commercial potential of AcelRx's product
candidates, including ARX-04 and Zalviso. These forward-looking
statements are based on AcelRx Pharmaceuticals' current
expectations and inherently involve significant risks and
uncertainties. AcelRx Pharmaceuticals' actual results and timing of
events could differ materially from those anticipated in such
forward-looking statements, and as a result of these risks and
uncertainties, which include, without limitation, risks related to
AcelRx Pharmaceuticals' ability to complete Phase 3 clinical
development of ARX-04 and support ARX-04 development under the
contract with the Department of Defense; AcelRx's ability to
successfully execute the pathway towards a resubmission of the
Zalviso NDA to the FDA, including the initiation and completion of
the IAP312 clinical study for Zalviso; any delays or inability to
obtain and maintain regulatory approval of its product candidates,
including ARX-04 in the United
States and Europe, and
Zalviso in the United States; the
uncertain clinical development process, including adverse events;
the risk that planned clinical trials may not begin on time, have
an effective clinical design, enroll a sufficient number of
patients, or be initiated or completed on schedule, if at all; the
success, cost and timing of all development activities and clinical
trials, including the Phase 3 ARX-04 SAP302 and SAP303 trials, and
the additional clinical trial for Zalviso, IAP312; the fact that
the FDA may dispute or interpret differently clinical results
obtained to date from the Phase 3 SAP301 study of ARX-04; the
market potential for AcelRx's product candidates; and other risks
detailed in the "Risk Factors" and elsewhere in AcelRx's U.S.
Securities and Exchange Commission filings and reports, including
its Annual Report on Form 10-Q filed with the SEC on May 2, 2016. AcelRx undertakes no duty or
obligation to update any forward-looking statements contained in
this release as a result of new information, future events or
changes in its expectations.
Logo -
http://photos.prnewswire.com/prnh/20130226/MM67303LOGO
To view the original version on PR Newswire,
visit:http://www.prnewswire.com/news-releases/acelrx-pharmaceuticals-to-present-at-two-upcoming-investor-events-in-may-300262283.html
SOURCE AcelRx Pharmaceuticals, Inc.